These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 21402292)
1. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder. Arlandis S; Castro D; Errando C; Fernández E; Jiménez M; González P; Crespo C; Staeuble F; Rodríguez JM; Brosa M Value Health; 2011; 14(2):219-28. PubMed ID: 21402292 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. Leong RK; de Wachter SG; Joore MA; van Kerrebroeck PE BJU Int; 2011 Aug; 108(4):558-64. PubMed ID: 21166750 [TBL] [Abstract][Full Text] [Related]
3. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. Bertapelle MP; Vottero M; Popolo GD; Mencarini M; Ostardo E; Spinelli M; Giannantoni A; D'Ausilio A World J Urol; 2015 Aug; 33(8):1109-17. PubMed ID: 25218855 [TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis Between Sacral Neuromodulation and OnabotulinumtoxinA for the Treatment of Refractory Overactive Bladder in Women: A Systematic Review. Gerjevic KA; Ahmad S; Strohbehn K; Riblet N Female Pelvic Med Reconstr Surg; 2021 Aug; 27(8):481-487. PubMed ID: 34074937 [TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK. Autiero SW; Hallas N; Betts CD; Ockrim JL BJU Int; 2015 Dec; 116(6):945-54. PubMed ID: 25407358 [TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of sacral neuromodulation in overactive bladder: A Canadian perspective. Hassouna MM; Sadri H Can Urol Assoc J; 2015; 9(7-8):242-7. PubMed ID: 26316906 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of sacral neuromodulation (SNM) with Interstim for fecal incontinence patients in Spain. Brosa M; Muñoz-Duyos A; Navarro-Luna A; Rodriguez JM; Serrano D; Gisbert R; Dziekan K; Segú JL Curr Med Res Opin; 2008 Mar; 24(3):907-18. PubMed ID: 18279582 [TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder. Tay LJ; Harry D; Malde S; Sahai A Urology; 2021 Mar; 149():1-10. PubMed ID: 33227305 [TBL] [Abstract][Full Text] [Related]
10. Mechanism and Priority of Botulinum Neurotoxin A versus Sacral Neuromodulation for Refractory Overactive Bladder: A Review. Zhang Y; Ji F; Liu E; Wen JG Urol Int; 2021; 105(11-12):929-934. PubMed ID: 34130295 [TBL] [Abstract][Full Text] [Related]
11. Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients. Reekmans M; Janssen JMW; Vrijens DMJ; Smits MAC; van Koeveringe GA; Van Kerrebroeck PEVA Neurourol Urodyn; 2021 Jun; 40(5):1120-1125. PubMed ID: 33829519 [TBL] [Abstract][Full Text] [Related]
12. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy. Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028 [TBL] [Abstract][Full Text] [Related]
16. Botox rechallenge-An additional tool in the management of an incompletely emptying bladder and inadequate overactive symptom control following sacral neuromodulation. Timm B; Jayarajan J; Chan G; Bolton D Low Urin Tract Symptoms; 2021 Jan; 13(1):194-197. PubMed ID: 32548938 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of overactive bladder treatments: from the US payer perspective. Murray B; Hessami SH; Gultyaev D; Lister J; Dmochowski R; Gillard KK; Stanisic S; Tung A; Boer R; Kaplan S J Comp Eff Res; 2019 Jan; 8(1):61-71. PubMed ID: 30511584 [TBL] [Abstract][Full Text] [Related]
18. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome. Noblett KL; Dmochowski RR; Vasavada SP; Garner AM; Liu S; Pietzsch JB Neurourol Urodyn; 2017 Mar; 36(3):727-733. PubMed ID: 27062384 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder. Chen HW; Bercik RS; Werner EF; Thung SF J Urol; 2012 Jan; 187(1):178-84. PubMed ID: 22100006 [TBL] [Abstract][Full Text] [Related]
20. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review. Leong RK; De Wachter SG; van Kerrebroeck PE Urol Int; 2010; 84(3):245-53. PubMed ID: 20389150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]